Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the sixth cause of death from cancer in the USA. Autologous stem cell transplantation (ASCT) is a potentially curative therapeutic option for many NHL patients. Choosing the most effective conditioning regimen prior to ASCT can lead to longer survival in these patients, and, as in many cases of high risk NHL, the only potentially curative option is stem cell transplantation. Radioimmunotherapy (RIT) is based on using radiolabeled monoclonal antibodies against tumoral antigens. Since lymphoma cells are sensitive to radiation, RIT has become a potential approach in treating NHL. In this review, we have discussed the efficacy and safety of RIT as an alternative conditioning regimen prior to ASCT.
Keyphrases
- stem cell transplantation
- high dose
- end stage renal disease
- newly diagnosed
- prognostic factors
- chronic kidney disease
- peritoneal dialysis
- diffuse large b cell lymphoma
- cell therapy
- stem cells
- induced apoptosis
- squamous cell carcinoma
- patient reported outcomes
- radiation therapy
- oxidative stress
- risk assessment
- immune response
- papillary thyroid
- cell proliferation
- young adults
- patient reported
- endoplasmic reticulum stress